C.L. has received grants from Genentech/imCORE. T.K.C. reports institutional and personal, paid and unpaid support for research, advisory boards, consultancy and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, and Up-To-Date, and for CME events from Peerview, OncLive, MJH and others, outside of the submitted work; institutional patents filed on molecular alterations and immunotherapy response/toxicity, and ctDNA; equity in Osel, Pionyr, Precede Bio, and Tempest; committee membership for ACCRU, ASCO, ESMO, KidneyCan and the NCCN GU Steering Committee; medical writing and editorial assistance support that might have been funded in part by communications companies; mentorship of several non-US citizens on research projects with potential funding, in part, from non-US sources/foreign components. The institution of C.L. and T.K.C. (Dana-Farber Cancer Institute) might have received additional independent funding from pharmaceutical companies and/or royalties potentially involved in research around the subject matter.